TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.
Brief Summary: This trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (PEP) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).


Options:
A: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
B: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.
Brief Summary: This trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (PEP) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).


Options:
A: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2
C: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%
D: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.
Brief Summary: This trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (PEP) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).


Options:
A: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
B: Arm Label: Cycling in combination with Flutter® therapy; Type: EXPERIMENTAL; Interventions: Device: Flutter® | Arm Label: Cycling without Flutter® therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: No Flutter® | Intervention Type: DEVICE; Name: Flutter®; Assigned to Arm(s): Cycling in combination with Flutter® therapy | Intervention Type: DEVICE; Name: No Flutter®; Assigned to Arm(s): Cycling without Flutter® therapy
C: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
D: Intervention Type: DEVICE; Name: High frequency chest wall oscillator; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.
Brief Summary: This trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (PEP) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).


Options:
A: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
B: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.
Brief Summary: This trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (PEP) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).


Options:
A: Arm Label: Autogenic drainage; Type: OTHER; Interventions: Other: Autogenic drainage | Intervention Type: OTHER; Name: Autogenic drainage; Assigned to Arm(s): Autogenic drainage
B: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
C: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.
Brief Summary: This trial aims to analyze whether the inhalation of hypertonic saline combined with a positive expiratory pressure (PEP) device increases the amount of sputum expectorated during the chest physiotherapy session ( inhalation + bronchial drainage).


Options:
A: Arm Label: Normal airway clearance; Type: EXPERIMENTAL; Interventions: Other: Airway Clearance Techniques | Arm Label: Non-Invasive Ventilation; Type: EXPERIMENTAL; Interventions: Other: Airway Clearance Techniques | Intervention Type: OTHER; Name: Airway Clearance Techniques; Assigned to Arm(s): Non-Invasive Ventilation, Normal airway clearance
B: Arm Label: USUAL CARE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: INHALATION WITH PEP DEVICE; Type: ACTIVE_COMPARATOR; Interventions: Device: INHALATION WITH PEP DEVICE (Acapella Duet) | Intervention Type: DEVICE; Name: INHALATION WITH PEP DEVICE (Acapella Duet); Assigned to Arm(s): INHALATION WITH PEP DEVICE
C: Arm Label: Usual Airway Clearance Technique; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual airway clearance | Arm Label: High Frequency Chest Wall Oscillation (HFCWO); Type: EXPERIMENTAL; Interventions: Device: High Frequency Chest Wall Oscillation (HFCWO) | Intervention Type: DEVICE; Name: High Frequency Chest Wall Oscillation (HFCWO); Assigned to Arm(s): High Frequency Chest Wall Oscillation (HFCWO) | Intervention Type: OTHER; Name: Usual airway clearance; Assigned to Arm(s): Usual Airway Clearance Technique
D: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC
Brief Summary: Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.


Options:
A: Arm Label: Sequential D + T, THEN Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Concurrent D + T AND Pembrolizumab; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib, Drug: Pembrolizumab | Arm Label: Pembrolizumab ONLY; Type: EXPERIMENTAL; Interventions: Drug: Pembrolizumab | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Sequential D + T, THEN Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Concurrent D + T AND Pembrolizumab, Pembrolizumab ONLY, Sequential D + T, THEN Pembrolizumab
B: Arm Label: vemurafenib + cobimetinib + atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib, Drug: Atezolizumab | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab
C: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: Domatinostat; Assigned to Arm(s): B, C, D | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): A, B, C, D | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): D

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Treatment With the Combination of Vemurafenib, Cobimetinib and Atezolizumab in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed, Two Cohort, Phase II EADO Trial NEO-VC
Brief Summary: Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ipilimumab (MDX-010, BMS-734016) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab | Intervention Type: DRUG; Name: ipilimumab (MDX-010, BMS-734016); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): 3
B: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
C: Arm Label: vemurafenib + cobimetinib + atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib, Drug: Atezolizumab | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: Domatinostat; Assigned to Arm(s): B, C, D | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): A, B, C, D | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial
Brief Summary: 200 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).


Options:
A: Arm Label: Primary prevention; Type: OTHER; Interventions: Drug: Misoprostol | Arm Label: Secondary Prevention; Type: OTHER; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Secondary Prevention | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Primary prevention
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
C: Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Ergometrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ergometrine | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Ergometrine; Assigned to Arm(s): Ergometrine
D: Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Ultrasound Guided Foam Sclerotherapy Versus Classical Surgical Stripping Study
Brief Summary: The aim of this study is to investigate the long-term follow-up of the previously conducted FOAM study.


Options:
A: Arm Label: High ligation and stripping (surgery); Type: N/A; Interventions: N/A | Arm Label: Foam sclerotherapy; Type: N/A; Interventions: N/A
B: Arm Label: VenaSeal SCS; Type: EXPERIMENTAL; Interventions: Device: VenaSeal SCS | Arm Label: RFA (ClosureFast); Type: ACTIVE_COMPARATOR; Interventions: Device: ClosureFast Radiofrequency Ablation (RFA) | Arm Label: Roll-in (VenaSeal SCS); Type: EXPERIMENTAL; Interventions: Device: Roll-in (VenaSeal SCS) | Intervention Type: DEVICE; Name: VenaSeal SCS; Assigned to Arm(s): VenaSeal SCS | Intervention Type: DEVICE; Name: ClosureFast Radiofrequency Ablation (RFA); Assigned to Arm(s): RFA (ClosureFast) | Intervention Type: DEVICE; Name: Roll-in (VenaSeal SCS); Assigned to Arm(s): Roll-in (VenaSeal SCS)
C: Arm Label: CE Marked Sapheon Closure System in GSV; Type: EXPERIMENTAL; Interventions: Device: CE Marked Sapheon Closure System | Intervention Type: DEVICE; Name: CE Marked Sapheon Closure System; Assigned to Arm(s): CE Marked Sapheon Closure System in GSV
D: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery - Saphenofemoral ligation, saphenous strip and avulsions | Arm Label: EVLT; Type: EXPERIMENTAL; Interventions: Procedure: EVLT | Intervention Type: PROCEDURE; Name: Surgery - Saphenofemoral ligation, saphenous strip and avulsions; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: EVLT; Assigned to Arm(s): EVLT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health
Brief Summary: The purpose of this study to assess the effect of maternal vitamin D3 (cholecalciferol) supplementation on maternal HIV progression, small-for-gestational age infants, and infant stunting at 12 months postpartum for HIV-infected Tanzanian pregnant women who are receiving highly active antiretroviral therapy (HAART).


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Calcium plus vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Calcium plus vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium plus vitamin D; Assigned to Arm(s): Calcium plus vitamin D
B: Arm Label: Vitamin D3 (cholecalciferol); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D3 (cholecalciferol) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Study group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: D Max drops | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: D Max drops; Assigned to Arm(s): Study group
D: Arm Label: 10 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mcg Vitamin D3 | Arm Label: 20 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 20 mcg Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mcg Vitamin D3; Assigned to Arm(s): 10 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 20 mcg Vitamin D3; Assigned to Arm(s): 20 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B